Phenobarbital Should NOT Be Used Long-Term for Anxiety
Phenobarbital is not an appropriate medication for long-term anxiety treatment and should be avoided for this indication. While the FDA label indicates phenobarbital can be used for "anxiety-tension states," this approval reflects historical prescribing patterns from decades ago and does not align with current evidence-based psychiatric practice 1.
Why Phenobarbital Is Inappropriate for Anxiety
Outdated and Inferior Treatment Option
The evidence clearly demonstrates that phenobarbital is an obsolete choice for anxiety disorders:
No modern guideline support: Contemporary anxiety treatment guidelines do not recommend barbiturates for anxiety management. A comprehensive 2016 systematic review of long-term pharmacological treatments for anxiety disorders found evidence supporting paroxetine, escitalopram, clonazepam for panic disorder, and pregabalin and quetiapine for generalized anxiety disorder—but no barbiturates 2.
Better alternatives exist: Modern first-line treatments include SSRIs, SNRIs, and when appropriate, benzodiazepines for short-term use. A 2007 critical review of anticonvulsants in anxiety disorders found the strongest evidence for pregabalin, lamotrigine, and gabapentin—not phenobarbital 3.
Significant Safety Concerns with Long-Term Use
Long-term phenobarbital use carries substantial risks that outweigh any potential anxiolytic benefit:
Tolerance without safety margin: While users develop tolerance to sedative effects, they do NOT develop tolerance to lethal respiratory depression. This means long-term users can tolerate higher doses but remain at risk of fatal toxicity at similar serum concentrations 4.
Dangerous drug interactions: Phenobarbital is a potent CYP450 enzyme inducer, significantly altering metabolism of other medications. When combined with other CNS depressants (alcohol, opioids, benzodiazepines), the risk of overdose increases dramatically due to additive respiratory depression 4.
Severe withdrawal risk: Abrupt discontinuation poses serious dangers, and long-term users face greater withdrawal risks 4.
Adverse Effect Profile
The FDA label documents concerning adverse effects that are particularly problematic for anxiety patients 1:
- CNS effects: Somnolence, confusion, psychiatric disturbance, hallucinations, paradoxically increased anxiety, nightmares, and thinking abnormalities
- Cardiovascular: Bradycardia, hypotension, syncope
- Respiratory: Hypoventilation, apnea
- Serious dermatologic reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis
Limited and Contradictory Efficacy Data
The research evidence for phenobarbital's anxiolytic effects is weak and contradictory:
Animal studies show simultaneous anxiolytic AND aversive effects, suggesting the drug induces an unpleasant state even while reducing some anxiety measures 5.
The "one-trial tolerance" phenomenon demonstrates that phenobarbital's anxiolytic effects are abolished with prior exposure in animal models 6.
No modern clinical trials support phenobarbital for anxiety treatment in humans.
What Should Be Used Instead
For anxiety disorders, evidence-based first-line treatments include:
- SSRIs/SNRIs (paroxetine, escitalopram, duloxetine, venlafaxine) for long-term management
- Pregabalin for generalized anxiety disorder and social anxiety disorder 2, 3
- Cognitive-behavioral therapy as monotherapy or combined with medication
- Short-term benzodiazepines (if needed) with careful monitoring and time-limited use, recognizing their own dependence risks 7
Clinical Bottom Line
Phenobarbital has no role in modern anxiety treatment. Its FDA indication for "anxiety-tension states" is a historical artifact that does not reflect current evidence-based practice. The combination of limited efficacy, significant adverse effects, dangerous drug interactions, tolerance development, withdrawal risks, and availability of superior alternatives makes phenobarbital an inappropriate choice for anxiety management—whether short-term or long-term.
If a patient is currently taking phenobarbital for anxiety, work with them to carefully taper and transition to evidence-based treatments rather than continuing this outdated and potentially dangerous therapy.